HRQoL in Advanced Soft Tissue Sarcoma Patients Treated With Chemotherapy.

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Aug 2, 2018

Keywords

ClinConnect Summary

Eligible patients with advanced soft tissue sarcoma will be introduced to this study by their hospital consultant during their routine outpatient appointment. Before deciding if he/she would like to take part, the patient will be provided with a patient information sheet which describes the study in detail. Participation in the study is entirely voluntary and their care will not be affected if he/she chooses not to take part.

The patient information sheet explains that this study involves completing regular questionnaires online, or by paper-and-pencil, about health-related quality of life...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Diagnosis of advanced (not amenable to curative surgical resection) soft tissue sarcoma (histology confirmed by sarcoma histopathologist)
• • Starting 1st line palliative chemotherapy or 3rd line palliative chemotherapy according to standard treatment guidelines.
• • Able to communicate in English
• • Mental capacity to provide informed consent and to participate in the study (as determined by the treating physician).
• • Patients must be able to complete questionnaires themselves (a prerequisite for 'patient reported outcome' data).
• • Patients must be under treatment or follow-up at one of the participating centres
• Exclusion Criteria:
• • Patients with GIST, Ewing sarcoma, rhabdomyosarcoma and desmoplastic small round cell tumour.
• • Patients who have already started 1st line or 3rd chemotherapy.
• • Patients who are too ill to receive any further systemic treatment (death is imminent), as determined by the referring health care professional